Japan approves world's first commercial stem-cell treatments for Parkinson's and heart failure

yahoo.com

Japan has approved the world's first commercial stem-cell treatments for Parkinson's disease and severe heart failure. The treatments, Amchepry for Parkinson's and ReHeart for heart failure, use induced pluripotent stem cells and could be available to patients this summer. These iPS cell therapies, developed by Sumitomo Pharma and Cuorips respectively, offer new hope for patients worldwide.


With a significance score of 5.5, this news ranks in the top 1% of today's 30609 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: